论文部分内容阅读
目的研究吉西他滨联合奥沙利铂治疗晚期恶性肿瘤的近期疗效和血液学不良反应。方法吉西他滨1000mg/m~2,第1、8天静脉给药,奥沙利铂130mg/m~2,第1天静脉给药,21 d为1疗程,治疗44例晚期恶性肿瘤患者。结果 44例中卵巢癌患者有效率为55.6%(10/18例),肺癌有效率为50%(3/6例),淋巴瘤有效率为83.3%(5/6例),胰腺癌有效率为16.7%(1/6例),肝细胞癌有效率为50%(2/4例),胆囊癌和胆管癌有效率为25%(1/4例)。治疗过程中出现了较为明显的血液学不良反应,44例患者治疗181疗程中,出现Ⅲ～Ⅳ度中性粒细胞减少的占50%(22/44例)、35.9%(65/181疗程);血小板下降40.9%(18/44例)、25.9%(47/181疗程);红细胞下降18.2%(8/44例)、13.8%(25/181疗程)。8例患者需要输注血小板,5例患者需要输注红细胞。结论吉西他滨联合奥沙利铂对晚期恶性肿瘤是一个有明显活性的化疗方案,但也有较明显的血液学不良反应。
Objective To study the short-term efficacy and adverse reactions of gemcitabine plus oxaliplatin in the treatment of advanced malignancies. Methods Gemcitabine was administered intravenously at day 1 and day 8, intravenous administration of oxaliplatin at day 1 and day 8, and intravenous administration of oxaliplatin at day 1 for 21 courses of treatment for 44 patients with advanced malignant tumor. Results The effective rate of ovarian cancer in 44 cases was 55.6% (10/18 cases), the effective rate of lung cancer was 50% (3/6 cases), the effective rate of lymphoma was 83.3% (5/6 cases), the effective rate of pancreatic cancer 16.7% (1/6 cases), the effective rate of hepatocellular carcinoma was 50% (2/4 cases), and the effective rate of gallbladder carcinoma and cholangiocarcinoma was 25% (1/4 case). In the course of treatment, obvious hematological adverse reactions occurred. Among the 44 patients who received 181 courses of treatment, 50% (22/44 cases) had Ⅲ ~ Ⅳ neutropenia and 35.9% (65/181 courses) ; Thrombocytopenia 40.9% (18/44 cases), 25.9% (47/181 courses); erythrocyte decreased 18.2% (8/44 cases) and 13.8% (25/181 courses). Eight patients required platelet transfusions and five required red blood cell transfusions. Conclusion Gemcitabine combined with oxaliplatin is a significant active chemotherapy regimen for advanced malignancies, but there are also obvious hematological adverse reactions.